

# **Global Superdisintegrants Market Size study, by Type (Natural, Synthetics, Others), Formulation (Tablets, Capsules), Therapeutic Area (Neurological Diseases, Gastrointestinal Diseases, Oncology, Inflammatory Diseases, Infectious Diseases, Cardiovascular Diseases, Hematological Diseases) and Regional Forecasts 2019-2026**

<https://marketpublishers.com/r/G1C1B87038EEN.html>

Date: June 2019

Pages: 200

Price: US\$ 3,950.00 (Single User License)

ID: G1C1B87038EEN

## **Abstracts**

Global superdisintegrants market is valued at approximately USD 349.60 million in 2018 and is anticipated to grow with a healthy growth rate of more than 8.10% over the forecast period 2019-2026. Superdisintegrants are combination of substances added to drug formulation that accelerates the disintegration of capsule content or tablets into smaller particles which easily gets dissolved. Increasing adoption of oral disintegrating tablets is one of the major driving factors of global superdisintegrants market. In addition, shifting focus of pharmaceutical manufacturers towards emerging markets is an added advantage for the growth of market. However, less expenditure in R&D activities restricts the market to grow with the expected rate. For instance, the fragmentation of the EU pharmaceutical market resulted in lucrative parallel trade. Neither social security nor patients are benefitted with this and leads to deprival of additional resources for funding R&D.

The regional analysis of global Superdisintegrants market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to rising adoption of synthetic superdisintegrants. Europe also contributes a satisfactory growth in the global Superdisintegrants market due to rising population affected by neurological diseases. Asia-Pacific is also anticipated to exhibit

higher growth rate / CAGR over the forecast period 2019-2026 due to increasing preference to ODTs in developing countries such as India China and Japan.

The leading market player included in this report are:

BASF SE  
DowDuPont Inc.  
Roquette Freres  
DFE Pharma  
JRS Pharma  
Asahi Kasei Corporation  
Merck KGaA  
Corel Pharma Chem  
Avantor Performance Materials, LLC  
Ashland Global Holdings Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Natural  
Synthetic  
Others

By Formulation:

Tablets  
Capsules

By Therapeutic Area:

Neurological Diseases

Gastrointestinal Diseases  
Oncology  
Inflammatory Diseases  
Infectious Diseases  
Cardiovascular Diseases  
Hematological Diseases

By Regions:

North America  
U.S.  
Canada  
Europe  
UK  
Germany  
Asia Pacific  
China  
India  
Japan  
Latin America  
Brazil  
Mexico  
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017

Base year – 2018

Forecast period – 2019 to 2026

Target Audience of the Global Superdisintegrants Market in Market Study:

Key Consulting Companies & Advisors  
Large, medium-sized, and small enterprises  
Venture capitalists  
Value-Added Resellers (VARs)  
Third-party knowledge providers  
Investment bankers  
Investors

## Contents

### **CHAPTER 1. EXECUTIVE SUMMARY**

- 1.1. Market Snapshot
- 1.2. Key Trends
- 1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
  - 1.3.1. Superdisintegrants Market, by Type, 2016-2026 (USD Billion)
  - 1.3.2. Superdisintegrants Market, by Formulation, 2016-2026 (USD Billion)
  - 1.3.3. Superdisintegrants Market, by Therapeutic Area, 2016-2026 (USD Billion)
  - 1.3.4. Superdisintegrants Market, by Region, 2016-2026 (USD Billion)
- 1.4. Estimation Methodology
- 1.5. Research Assumption

### **CHAPTER 2. SUPERDISINTEGRANTS MARKET DEFINITION AND SCOPE**

- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
  - 2.2.1. Industry Evolution
  - 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates

### **CHAPTER 3. SUPERDISINTEGRANTS MARKET DYNAMICS**

- 3.1. See Saw Analysis
  - 3.1.1. Market Drivers
  - 3.1.2. Market Challenges
  - 3.1.3. Market Opportunities

### **CHAPTER 4. SUPERDISINTEGRANTS MARKET INDUSTRY ANALYSIS**

- 4.1. Porter's 5 Force Model
  - 4.1.1. Bargaining Power of Buyers
  - 4.1.2. Bargaining Power of Suppliers
  - 4.1.3. Threat of New Entrants
  - 4.1.4. Threat of Substitutes
  - 4.1.5. Competitive Rivalry
  - 4.1.6. Futuristic Approach to Porter's 5 Force Model

- 4.2. PEST Analysis
  - 4.2.1. Political Scenario
  - 4.2.2. Economic Scenario
  - 4.2.3. Social Scenario
  - 4.2.4. Technological Scenario
- 4.3. Key Buying Criteria (On Demand)
- 4.4. Regulatory Framework (On Demand)
- 4.5. Investment Vs Adoption Scenario (On Demand)
- 4.6. Analyst Recommendation & Conclusion

## **CHAPTER 5. SUPERDISINTEGRANTS MARKET, BY TYPE**

- 5.1. Market Snapshot
- 5.2. Market Performance - Potential Model
- 5.3. Key Market Players
- 5.4. Superdisintegrants Market, Sub Segment Analysis
  - 5.4.1. Natural Superdisintegrants
    - 5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 5.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 5.4.2. Synthetic Superdisintegrants
    - 5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 5.4.3. Other Superdisintegrants
    - 5.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 5.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

## **CHAPTER 6. SUPERDISINTEGRANTS MARKET, BY FORMULATION**

- 6.1. Market Snapshot
- 6.2. Market Performance - Potential Model
- 6.3. Key Market Players
- 6.4. Superdisintegrants Market, Sub Segment Analysis
  - 6.4.1. Capsules
    - 6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 6.4.2. Tablets
    - 6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

## **CHAPTER 7. SUPERDISINTEGRANTS MARKET, BY THERAPEUTIC AREA**

- 7.1. Market Snapshot
- 7.2. Market Performance - Potential Model
- 7.3. Key Market Players
- 7.4. Superdisintegrants Market, Sub Segment Analysis
  - 7.4.1. Gastrointestinal Diseases
    - 7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.2. Neurological Diseases
    - 7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.3. Inflammatory Diseases
    - 7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.4. Oncology
    - 7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.5. Cardiovascular Diseases
    - 7.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.6. Infectious Diseases
    - 7.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.7. Hematological Diseases
    - 7.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 7.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

## **CHAPTER 8. SUPERDISINTEGRANTS MARKET, BY REGIONAL ANALYSIS**

- 8.1. Superdisintegrants Market, Regional Market Snapshot (2016-2026)
- 8.2. North America Superdisintegrants Market Snapshot
  - 8.2.1. U.S.
    - 8.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.2.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.2.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.2.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.2. Canada
    - 8.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)

- 8.2.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.2.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.2.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.3. Europe Superdisintegrants Market Snapshot
  - 8.3.1. U.K.
    - 8.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.2. Germany
    - 8.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.3. Rest of Europe
    - 8.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.3.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.3.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.3.3.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4. Asia Superdisintegrants Market Snapshot
  - 8.4.1. China
    - 8.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.4.2. India
    - 8.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.4.3. Japan
    - 8.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.3.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.3.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.3.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.4.4. Rest of Asia Pacific
    - 8.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.4.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.4.4.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)



- 8.4.4.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.5. Latin America Superdisintegrants Market Snapshot
  - 8.5.1. Brazil
    - 8.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.5.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.5.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.5.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.5.2. Mexico
    - 8.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.5.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.5.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.5.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.6. Rest of The World
  - 8.6.1. South America
    - 8.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.6.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.6.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.6.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.6.2. Middle East and Africa
    - 8.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
    - 8.6.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.6.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
    - 8.6.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)

## **CHAPTER 9. COMPETITIVE INTELLIGENCE**

- 9.1. Company Market Share (Subject to Data Availability)
- 9.2. Top Market Strategies
- 9.3. Company Profiles
  - 9.3.1. Ashland Global Holdings Inc.
    - 9.3.1.1. Overview
    - 9.3.1.2. Financial (Subject to Data Availability)
    - 9.3.1.3. Product Summary
    - 9.3.1.4. Recent Developments
  - 9.3.2. BASF SE
  - 9.3.3. DowDuPont Inc.
  - 9.3.4. Roquette Freres
  - 9.3.5. DFE Pharma
  - 9.3.6. JRS Pharma



- 9.3.7. Asahi Kasei Corporation
- 9.3.8. Merck KGaA
- 9.3.9. Corel Pharma Chem
- 9.3.10. Avantor Performance Materials, LLC

## **CHAPTER 10. RESEARCH PROCESS**

- 10.1. Research Process
  - 10.1.1. Data Mining
  - 10.1.2. Analysis
  - 10.1.3. Market Estimation
  - 10.1.4. Validation
  - 10.1.5. Publishing
  - 10.1.6. Research Assumption

## I would like to order

Product name: Global Superdisintegrants Market Size study, by Type (Natural, Synthetics, Others), Formulation (Tablets, Capsules), Therapeutic Area (Neurological Diseases, Gastrointestinal Diseases, Oncology, Inflammatory Diseases, Infectious Diseases, Cardiovascular Diseases, Hematological Diseases) and Regional Forecasts 2019-2026

Product link: <https://marketpublishers.com/r/G1C1B87038EEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1C1B87038EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970